Trial results

Epicardial Cardiac Fat-CT (EPIC-CT)

NCT07297589 on ClinicalTrials.gov · last registry update 2026-01-02

A small phase 3 — 136 participants, against a typical 424. Due to report January 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Epicardial fat. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status

RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Instituto Mexicano del Seguro Social

Sponsor type

Other Gov

Enrollment

136

Started

2025-12-30

Primary completion

2027-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Epicardial fat

Conditions studied

STEMI - ST Elevation Myocardial Infarction · Epicardial Fat

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.